FANHDI

This brand name is authorized in Brazil, Ecuador, Ireland, Poland, Romania, Singapore, Spain, Turkey, UK.

Active ingredients

The drug FANHDI contains one active pharmaceutical ingredient (API):

1	Coagulation factor VIII UNII 839MOZ74GK - ANTIHEMOPHILIC FACTOR HUMAN
	Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X (factor Xa). Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.
	Read more about Coagulation factor VIII

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02BD02	Coagulation factor VIII	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors
Discover more medicines within B02BD02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	510900901151319, 510900902158317, 510900904150313
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	H7351013, H7911113
ES	Centro de información online de medicamentos de la AEMPS	60600, 60601, 60602
GB	Medicines & Healthcare Products Regulatory Agency	174885, 47893, 47896
PL	Rejestru Produktów Leczniczych	100001485, 100212495, 100212510
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W43391001, W43392001, W43393001
SG	Health Sciences Authority	11521P, 11522P, 11523P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699769980030, 8699769980078, 8699769980122, 8699769980429